Go Deep
Fredun Pharmaceuticals Limited
Fredun Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,862 | 50.5 | 8.44 | 0.87 | 1,391.00 |
Fredun Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 2,277,555,000.0 | 2,104,120,000.0 | 1,599,263,000.0 | 1,435,853,000.0 |
| Net Profit | 131,323,000.0 | 107,800,000.0 | 104,780,000.0 | 94,317,000.0 |
| EPS | 7.9 | 6.6 | 7.4 | 6.7 |
Fredun Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 6,333,265,000.0 | 4,517,065,000.0 | 3,465,769,000.0 | 2,743,417,000.0 | — |
| Net Profit | 326,209,000.0 | 197,393,000.0 | 156,234,000.0 | 108,066,000.0 | — |
| EPS | 0.0 | 0.0 | 11.2 | 8.0 | — |
Fredun Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 6,420,823,000.0 | 4,874,113,000.0 | 3,075,991,000.0 | 2,572,795,000.0 | — |
| Total Liabilities | 3,604,610,000.0 | 3,460,287,000.0 | 1,861,279,000.0 | 1,609,038,000.0 | — |
| Total Equity | 2,816,214,000.0 | 1,413,826,000.0 | 1,214,712,000.0 | 963,757,000.0 | — |
Owes vs Owns
Fredun Pharmaceuticals Limited owed ₹0.56 for every ₹1 it owned in Mar 2026, down from ₹0.63 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.56× | 0.71× | 0.61× | 0.63× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Fredun Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 10.1%Receivables 14.4%Inventory 42.0%Fixed assets (tangible) 20.8%Long-term investments 2.1%Other assets 10.5%
How it's funded — Mar 2026
Short-term debt 25.9%Long-term debt 8.8%Payables 13.6%Other liabilities 7.8%Shareholders' equity 43.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 64.9 | 5.2 | 2.1 | 3.4 |
| Receivables | 92.7 | 177.1 | 64.8 | 34.6 |
| Inventory | 269.8 | 239.9 | 175.0 | 150.1 |
| Fixed assets (tangible) | 133.5 | 62.1 | 48.0 | 40.2 |
| Intangible assets | 0.6 | 0.4 | 0.4 | 0.3 |
| Long-term investments | 13.2 | 0.7 | 0.0 | 0.0 |
| Other assets | 67.3 | 2.0 | 17.2 | 28.6 |
| Liabilities & equity | ||||
| Short-term debt | 166.2 | 157.5 | 92.7 | 71.1 |
| Long-term debt | 56.3 | 9.6 | 12.8 | 15.4 |
| Payables | 87.6 | 144.8 | 62.9 | 59.3 |
| Other liabilities | 50.4 | 34.1 | 17.7 | 15.0 |
| Shareholders' equity | 281.6 | 141.4 | 121.5 | 96.4 |
| Net tangible assets | 281.0 | 141.0 | 121.1 | 96.1 |
Fredun Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 119,015,000.0 | -165,977,000.0 | -4,387,000.0 | -144,088,000.0 | — |
| Investing Activities | -735,908,000.0 | -63,542,000.0 | -76,391,000.0 | -94,045,000.0 | — |
| Financing Activities | 1,214,470,000.0 | 266,508,000.0 | 59,930,000.0 | 251,767,000.0 | — |